Cargando…
A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
BACKGROUND: Norm-based scores used to assess cognitive ability have clinical value when describing functioning of patients with neuronopathic disorders compared with unaffected, same-age peers. However, they have limitations when used to assess change in cognitive ability between two timepoints, esp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621086/ https://www.ncbi.nlm.nih.gov/pubmed/37915038 http://dx.doi.org/10.1186/s13023-023-02957-2 |
_version_ | 1785130338610053120 |
---|---|
author | Yee, Karen S. Chirila, Costel Davenport, Eric Mladsi, Deirdre Barnett, Christine Kronenberger, William G. |
author_facet | Yee, Karen S. Chirila, Costel Davenport, Eric Mladsi, Deirdre Barnett, Christine Kronenberger, William G. |
author_sort | Yee, Karen S. |
collection | PubMed |
description | BACKGROUND: Norm-based scores used to assess cognitive ability have clinical value when describing functioning of patients with neuronopathic disorders compared with unaffected, same-age peers. However, they have limitations when used to assess change in cognitive ability between two timepoints, especially in children with severe cognitive decline. Calculation of Projected Retained Ability Scores (PRAS) is a novel method developed to characterize absolute change in norm-based ability test scores. In this analysis, PRAS were calculated post hoc for children with mucopolysaccharidosis II (MPS II; Hunter syndrome) and early cognitive impairment in a 52-week phase 2/3 randomized controlled trial (RCT) and its extension study of intrathecal idursulfase (idursulfase-IT). Patients completing the first year of the extension after receiving idursulfase-IT in the RCT and extension (n = 32 of 34 enrolled) or the extension only (n = 15 of 15 enrolled) were categorized according to changes in Differential Ability Scales, Second Edition, General Conceptual Ability (DAS-II GCA) scores and PRAS at 1 and 2 years. Analyses were conducted in the overall population and a subpopulation aged < 6 years at baseline (idursulfase-IT in the RCT and extension [n = 27] and extension only [n = 12]). RESULTS: PRAS methodology differentiated patients with decreases in DAS-II GCA scores into three separate categories reflecting below-average cognitive growth rates, plateauing cognitive development, and deteriorating cognitive functioning. After 1 year in the RCT, 72.4% of patients who initiated idursulfase-IT had above-average or average cognitive growth rates in DAS-II GCA scores compared with 53.3% of those who did not receive idursulfase-IT; 6.9% versus 20.0% experienced deteriorating cognitive functioning. Similar results were seen in children aged < 6 years: 76% (idursulfase-IT group) versus 50% (no idursulfase-IT) had above-average or average cognitive growth rates in DAS-II GCA scores; 4% versus 17% had deteriorating cognitive functioning. The difference in the distributions of cognitive categories at 1 year in children aged < 6 years was significant (p = 0.048). At 2 years, the proportions of patients in different cognitive categories were more similar between treatment groups. CONCLUSIONS: PRAS methodology may help to differentiate changes in cognitive development in MPS II, and therefore may represent a valuable addition to existing approaches for interpreting changes in cognitive scores over time. Trial Registration: ClinicalTrials.gov NCT02055118 (registration date: 4 February 2014) and NCT02412787 (registration date: 9 April 2015). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02957-2. |
format | Online Article Text |
id | pubmed-10621086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106210862023-11-03 A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT Yee, Karen S. Chirila, Costel Davenport, Eric Mladsi, Deirdre Barnett, Christine Kronenberger, William G. Orphanet J Rare Dis Research BACKGROUND: Norm-based scores used to assess cognitive ability have clinical value when describing functioning of patients with neuronopathic disorders compared with unaffected, same-age peers. However, they have limitations when used to assess change in cognitive ability between two timepoints, especially in children with severe cognitive decline. Calculation of Projected Retained Ability Scores (PRAS) is a novel method developed to characterize absolute change in norm-based ability test scores. In this analysis, PRAS were calculated post hoc for children with mucopolysaccharidosis II (MPS II; Hunter syndrome) and early cognitive impairment in a 52-week phase 2/3 randomized controlled trial (RCT) and its extension study of intrathecal idursulfase (idursulfase-IT). Patients completing the first year of the extension after receiving idursulfase-IT in the RCT and extension (n = 32 of 34 enrolled) or the extension only (n = 15 of 15 enrolled) were categorized according to changes in Differential Ability Scales, Second Edition, General Conceptual Ability (DAS-II GCA) scores and PRAS at 1 and 2 years. Analyses were conducted in the overall population and a subpopulation aged < 6 years at baseline (idursulfase-IT in the RCT and extension [n = 27] and extension only [n = 12]). RESULTS: PRAS methodology differentiated patients with decreases in DAS-II GCA scores into three separate categories reflecting below-average cognitive growth rates, plateauing cognitive development, and deteriorating cognitive functioning. After 1 year in the RCT, 72.4% of patients who initiated idursulfase-IT had above-average or average cognitive growth rates in DAS-II GCA scores compared with 53.3% of those who did not receive idursulfase-IT; 6.9% versus 20.0% experienced deteriorating cognitive functioning. Similar results were seen in children aged < 6 years: 76% (idursulfase-IT group) versus 50% (no idursulfase-IT) had above-average or average cognitive growth rates in DAS-II GCA scores; 4% versus 17% had deteriorating cognitive functioning. The difference in the distributions of cognitive categories at 1 year in children aged < 6 years was significant (p = 0.048). At 2 years, the proportions of patients in different cognitive categories were more similar between treatment groups. CONCLUSIONS: PRAS methodology may help to differentiate changes in cognitive development in MPS II, and therefore may represent a valuable addition to existing approaches for interpreting changes in cognitive scores over time. Trial Registration: ClinicalTrials.gov NCT02055118 (registration date: 4 February 2014) and NCT02412787 (registration date: 9 April 2015). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02957-2. BioMed Central 2023-11-02 /pmc/articles/PMC10621086/ /pubmed/37915038 http://dx.doi.org/10.1186/s13023-023-02957-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yee, Karen S. Chirila, Costel Davenport, Eric Mladsi, Deirdre Barnett, Christine Kronenberger, William G. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title | A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title_full | A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title_fullStr | A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title_full_unstemmed | A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title_short | A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT |
title_sort | post hoc analysis of projected retained ability scores (pras) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis ii receiving intrathecal idursulfase-it |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621086/ https://www.ncbi.nlm.nih.gov/pubmed/37915038 http://dx.doi.org/10.1186/s13023-023-02957-2 |
work_keys_str_mv | AT yeekarens aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT chirilacostel aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT davenporteric aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT mladsideirdre aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT barnettchristine aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT kronenbergerwilliamg aposthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT yeekarens posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT chirilacostel posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT davenporteric posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT mladsideirdre posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT barnettchristine posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit AT kronenbergerwilliamg posthocanalysisofprojectedretainedabilityscoresprasforthelongitudinalassessmentofcognitivefunctioninginpatientswithneuronopathicmucopolysaccharidosisiireceivingintrathecalidursulfaseit |